Taken together, these results indicate that BAY-I treatment can effectively trigger long-term inhibition of tumor growth even after drug withdrawal by intratumorally activating CD8+ T cells, leading to clonal expansion and effector memory phenotype, most likely via TLS. This evidence concerns the gene CD8A and neoplasm.